Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 3;23(1):4.
doi: 10.1007/s11883-020-00900-5.

Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention

Aliza Hussain  1 , Mahmoud Al Rifai  1 , Dhruv Mahtta  1 , Jing Liu  1 , Vardhmaan Jain  2 , Salim S Virani  3   4
Affiliations
Review

Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention

Aliza Hussain et al. Curr Atheroscler Rep. .

Abstract

Purpose of the review: This review highlights late-breaking science presented at the American Heart Association Scientific Session 2020 that demonstrated advancements in preventative cardiology and introduced novel treatment approaches for the management of chronic kidney disease, type 2 diabetes, and/or heart failure.

Recent findings: The studies reviewed include clinical trials that assessed the use of omecamtiv in the treatment of heart failure with reduced heart failure (GALACTIC-HF); effects of sotagliflozin in patients with diabetes and recent heart failure exacerbation; cardiovascular outcomes with the use of omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH) and omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI); efficacy and safety of evinacumab in patients with refractory hypercholesterolemia; and the use of coronary computed tomography angiography for the assessment of suspected acute coronary syndrome. In addition, we review the results of the International Polycaps Study (TIPS-3) on the use of a polypill for the primary prevention of cardiovascular disease in intermediate-risk people. Finally, we discuss the SAMSON trial-a three-arm-N-of-1 trial-to identify the root cause of the symptoms contributing to patient nonadherence to statin therapy. The studies presented at the American Heart Association Scientific Session 2020 represent remarkable contributions in the field of cardiovascular disease and prevention.

Keywords: Cardiovascular prevention; Coronary computed tomography angiography; Omega-3 fatty acids; Polypill; Sodium-glucose co-transporter inhibitors; Statins.

PubMed Disclaimer

Conflict of interest statement

Salim S. Virani reports grants from Department of Veterans Affairs, World Heart Federation, Tahir and Jooma Family, and other from American College of Cardiology (Honorarium in my role as the Associate Editor for Innovations [acc.org]).

The other authors declare that they have no conflict of interest.

References

    1. Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al. Cardiac myosin activation with Omecamtiv Mecarbil in systolic heart failure. N Engl J Med. 2020. 10.1056/NEJMoa2025797Randomized controlled trial showing that the primary outcome of cardiovascular death or heart failure was significantly reduced among patients with heart failure with reduced ejection fraction, New York Heart Association (NYHA) functional class II-IV and LVEF ≤35% receiving omecamtiv mecarbil compared to placebo.
    1. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020. 10.1056/NEJMoa2030183In patients with a recent admission with HF and previous diagnosis of T2DM, sotagliflozin, when compared to placebo, significantly reduced rate of primary endpoint (cardiovascular mortality, HF hospitalizations).
    1. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020. 10.1001/jama.2020.22258In a multi-centric, double-blinded, randomized, placebo-controlled trial of 13,078 patients with either established ASCVD, diabetes or or high-risk primary prevention patients on maximally tolerated statin therapy, use of of omega-3 CA failed to show significant reduction in cardiovascular events among patients with use compared with corn oil. - PMC - PubMed
    1. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation. 2020. 10.1161/CIRCULATIONAHA.120.052209. - PubMed
    1. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, Khilla N, Hamlin R, Pordy R, Dong Y, Son V, Gaudet D. Evinacumab in Patients with Refractory Hypercholesterolemia. N Engl J Med. 2020 Dec 10;383(24):2307–19. 10.1056/NEJMoa2031049. - PubMed

MeSH terms